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Abstract
 
In spontaneous inflam m atory arthritis of K/BxN  T cell receptor transgenic m ice, the effector
phase of the disease is provoked by binding of im m unoglobulins (Igs) to joint surfaces. Inflam m a-
tory cytokines are known to be involved in hum an inflam m atory arthritis, in particular rheu-
m atoid arthritis, although, overall, the pathogenetic m echanism s of the hum an affliction rem ain
unclear. To explore the analogy between the K/BxN  m odel and hum an patients, we assessed
the role and relative im portance of inflam m atory cytokines in K/BxN  joint inflam m ation by
transferring arthritogenic serum  into a panel of genetically deficient recipients. Interleukin (IL)-1
proved absolutely necessary. Tum or necrosis factor (TN F)–
 
 was also required, although
seem ingly less critically than IL-1, because a proportion of TN F-
  
–deficient m ice developed
robust disease. There was no evidence for an im portant role for IL-6. Bone destruction and re-
construction were also exam ined. W e found that all m ice with strong inflam m ation exhibited
the bone erosion and reconstruction phenom ena typical of K/BxN  arthritis, with no evidence
of any particular requirem ent for TN F
  
 for bone destruction. The variability in the require-
m ent for TN F-
 
, rem iniscent of that observed in treated rheum atoid arthritis patients, did not
appear genetically program m ed but related instead to subtle environm ental changes.
Key words: transgenic • cytokine • knockout • inflam m atory • TN F
 
Introduction
 
Inflam m atory arthritides, in particular rheum atoid arthritis,
have been the focus of intense investigation, but their etiol-
ogy and pathogenesis rem ain controversial. There is no
consensus on what initiates rheum atoid arthritis (R A)
 
*
 
; i.e.,
whether it is prim arily an autoim m une response, an in-
flam m atory response to som e persisting m icrobial invasion,
or a com bination of the two. There is also dispute over the
leukocyte populations that are involved in the initiation of
joint inflam m ation. The paradigm  currently dom inating
the field portrays antigen-specific T cells in the joint as in-
citing the inflam m atory cascade by triggering m acrophages
and synoviocytes (1, 2), but this scenario has been ques-
tioned for a lack of direct experim ental dem onstration of
certain of its key points, and because of som e discordant
observations, such as the paucity of T cell–derived cyto-
kines in inflam ed joints (3). In contrast, a role for inflam m a-
tory cytokines like TN F-
 
 and IL-1 is well established (4),
m ost dem onstratively by the im pressive effect of therapeu-
tic protocols that block TN F–TN F-R  interactions (1).
There has also been debate on the relative im portance of
the IL-1 and TN F-
  
 pathways (4). It has also been noted
that, even in the best of trial outcom es, arthritis is not fully
reversed and roughly one third of R A patients are refrac-
tory to TN F–TN FR -blocking drugs.
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Inflam m atory Cytokines in K/BxN  Arthritis
The K/BxN  TCR  transgenic m ouse is a recently devel-
oped m odel of inflam m atory arthritis (5–9). All K/BxN  an-
im als spontaneously show an autoim m une disease with
m ost (although not all) of the clinical, histological, and im -
m unological features of R A in hum ans. The disorder is
critically dependent on both T and B cells. Although the
pathologic m anifestations are joint-specific, the process is
initiated, and then perpetuated, by dual T/B cell autoreac-
tivity to a ubiquitously expressed antigen, glucose-6-phos-
phate isom erase (GPI). Transfer of anti-GPI Igs from  ar-
thritic K/BxN  m ice into healthy anim als provokes arthritis
within days, even when the recipients are devoid of lym -
phocytes. GPI–anti-GPI im m une com plexes (Ics) are the
link between the system ic T and B lym phocyte autoreac-
tivity and the ensuing joint-specific inflam m ation and de-
struction; the joint specificity is perhaps a reflection of the
presence of GPI on the articular cavity surface (10). Initia-
tion of the inflam m atory effector phase requires both the
com plem ent network and Fc receptors (11). The relevance
of the K/BxN  m odel to hum an R A is supported by a re-
cent report that serum  from  alm ost two thirds of R A pa-
tients contained anti-GPI Abs, absent from  serum  of nor-
m al individuals or of patients with Lym e arthritis or
Sjogren’s syndrom e (12), although m ore recent data show
less obvious a correlation (unpublished data). The observa-
tion of GPI and GPI–anti-GPI com plexes on cartilage sur-
faces of hum an joints is also of interest (10).
O ur early studies on K/BxN  m ice revealed augm ented
local synthesis of inflam m atory cytokines, such as IL-6 and
TN F-
  
, in arthritic joints (5). H owever, the functional rel-
evance of this observation was not tested, other than a re-
port that failed to dem onstrate a required role for TN F-
 
(13). The role of inflam m atory cytokines is an im portant
elem ent to consider in attem pting to relate the m echanisti-
cally defined m ouse m odel to hum an R A patients. For ex-
am ple, does Ig-induced arthritis correspond to the TN F
  
-
dependent form  of the hum an disease or rather to the
variants resistant to TN F
 
/TN FR  blockade?
H ere, we apply the K/BxN  serum  transfer system  to a
panel of m ice deficient in one or m ore inflam m atory cyto-
kines or their receptors. A critical role for IL-1 is estab-
lished, along with a strong, but not absolute, requirem ent
for TN F
  
. Interestingly, we find that the requirem ent for
TN F
 
 varies m arkedly from  individual to individual, as it
does in hum ans.
 
M aterials and M ethods
 
M ice.
 
The knockout m ice used for serum  transfer were ob-
tained from  the Jackson Laboratory, brought to our anim al facility
at the H arvard M edical School anim als facility at 4–5 wk of age,
and used 1–3 wk later (in rare exceptions, the m ice were bred in
our colony). These m ice include the following: IL-6
  
/
  
 (14) on
a B6 background; IL-1r1
  
/
  
 on both B6 (15) and (B6 
  
 129)F2
(16) backgrounds; TN F
  
/
  
 (17) on a (B6 
  
 129)F2 back-
ground; Lta
  
/
  
 on the (B6 
 
 129)F2 background (18);
TN FR 1 /  (19) and TN FR 2 /  (20) on a B6 background;
and TN FR 1/2 /  (21) on a (B6  129)F2 background.
RNA Analysis. R N A was prepared from  ankle tissue by a
m odification of the LiCl/urea technique (22), designed to avoid
contam ination of the joint R N A with bone m arrow–derived m a-
terial by leaving the bone intact. After dissection of ankles (sec-
tioned at the long bones of the lower leg and in the m etatarsal
area), the tissue was freed of skin and superficial tendons. The
joint was im m ersed in 1 m l R N A solubilization solution (6 M
urea, 2% SDS). Articular cavities were opened with a scalpel and
were exposed to the m edium  to release the cellular contents. Af-
ter 10-m in incubation, the fragm ent was rem oved, and an equal
volum e of concentrated LiCl solution (6 M  LiCl, 6 M  urea, and
10 m M  sodium  acetate, pH  5) was added to precipitate the
R N A. cDN A was synthesized from  these R N As by M uLV re-
verse transcriptase (GIBCO  BR L).
Cyclophilin was used as an endogenous control using a probe
concentration of 200 and 400 nM  for each prim er in each reac-
tion. The probe and prim ers sequences used are as follows: probe,
5  VIC CTTGGGCCGCGTCTCCTT TAM R A 3 ; forward
prim er, 5  CAGACGCCACTGTCGCTTT 3 ; and reverse
prim er, 5  TGTCTTTGGAACTTTGTCTGCAA 3 . For the
quantification of TN F  and IL6, the TaqM an predeveloped assay
reagents were used (PE, Applied Biosytem s). For IL1 , the
probe and prim er concentrations per reaction were the sam e as
those used for cyclophilin. The probe and prim ers sequences used
are as follows: probe, 5  FAM  TGCAGCTGGAGAGTGTG-
GATCCCA TAM R A 3 ; forward prim er, 5  TGAAAGACG-
GCACACCCA 3 ; and reverse prim er, 5  AAACCGCTTTTC-
CATCTTCTTCT 3 . To determ ine relative expression values,
CT (CT cytokine  CT cyclophilin) was used to derive an ex-
pression index (2 CT), which was then divided by the sam e index
obtained with a reference sam ple of total spleen R N A.
Serum Transfer Protocol and Arthritis Scoring. K/BxN  serum
pools were prepared from  arthritic m ice 60 d old. Arthritis was
induced by intraperitoneal injection of 150–200 l serum  at days
0 and 2. A clinical index was evaluated over tim e (1 point for
each affected paw; 0.5 points for a paw with only m ild swelling/
redness or only a few digits affected). Ankle thickness was m ea-
sured by a caliper (6), with ankle thickening being defined as the
difference in ankle thickness from  the day 0 m easure.
Histology. H ind lim bs were collected and the knee and ankle
joints were separated m id-tibia. Specim ens were dissected to re-
m ove skin and outer m uscle, and subsequently fixed in 4%
paraform aldehyde for a m inim um  of 12 h and dem ineralized for
2 wk in 14% EDTA, followed by paraffin em bedding (m odel
Citadel 1000; Shandon). For each specim en, twenty 4- m  sagit-
tal serial sections were cut, and every fifth section was stained
with hem atoxylin and eosin (Sigm a-Aldrich) for evaluation of in-
flam m ation, bone erosion, and cartilage destruction. An adjacent
section was stained with toluidine blue (Sigm a-Aldrich) for spe-
cific evaluation of proteoglycan. H istopathological scoring was
perform ed as described previously (5, 23).
Results and D iscussion
Kinetics of Inflammatory Cytokine Production. Transfer of
K/BxN  serum  into norm al recipients induces rapid and
synchronous developm ent of arthritis, the first signs of joint
inflam m ation appearing within 24 h in fully susceptible
strains (9). To begin exploring the induction of various in-
flam m atory cytokines in this m odel and their tem poral re-
lationships, we m easured the expression of their m R N As
by quantitative real-tim e PCR . C57Bl/6 m ice were in-
 on M
arch 15, 2015
jem
.rupress.org
D
ow
nloaded from
 
Published July 1, 2002
79 Ji et al.
jected with a single dose of K/BxN  serum , R N A was pre-
pared at different tim es thereafter from  ankle tissue (pooled
from  two individuals), and real-tim e PCR  was perform ed
to quantitate spliced TN F- , IL-1
 
, and IL-6 m R N A
transcripts. A representative experim ent is shown in Fig. 1.
The first signs of induction were detectable a few hours
after serum  injection, with a m odest but detectable rise from
the baseline for all m R N As at 6 h. TN F
 
 m essage increased
m ore substantially from  24 h onwards. IL-1 transcripts fol-
lowed roughly the sam e pattern, but with a sharper induc-
tion at 48 h and far m ore extensive induction, reaching
13,000-fold at m axim um . IL-6 showed a delay, with a m ax-
im um  by 72 h followed by a decline at 144 h that was re-
producibly observed in several experim ents. These results
are consistent with an early appearance of inflam m atory cy-
tokine transcripts (from  cell recruitm ent, or from  true in-
duction of gene expression, or both), and a secondary, far
m ore extensive, induction. The induction of IL-1 appears
significantly m ore extensive than that of TN F-
 
.
 
No Role for IL-6.
 
The induction of arthritis by K/BxN
serum  transfer does not require any contribution from  T or
B cells (6). Thus, one can readily evaluate the role of in-
flam m atory cytokines purely on the effector phase of the
disease, unencum bered by their influences on the im m uno-
logical induction phase. Such com plications m ay have
clouded results from  collagen-induced arthritis (CIA) and
antigen-induced arthritis m odels, where the known pleio-
tropic effects of such cytokines on the structure or respon-
siveness of the im m une system  com plicate data interpreta-
tion. The K/BxN  serum  transfer system  is applicable to a
num ber of m ouse strains (9), allowing one to investigate
the effects of diverse natural and engineered m utations.
This strategy was applied here, focusing on the contribu-
tions of IL-1, IL-6, and m em bers of the TN F fam ily, by
transferring K/BxN  serum  into hom ozygous knockout
m ice lacking particular cytokines or cytokine receptors.
M ice of m atched genetic com position, bred in the sam e
colony, were used as controls. In m ost cases, we preferred
not to rely on injected cytokine inhibitors, such as anticy-
tokine antibodies or soluble receptor m olecules because
negative results with such reagents can be difficult to inter-
pret (sufficient dose or stability of the com pound? com -
pleteness of the blockade?). This is particularly an issue in a
context as aggressive as that of K/BxN  arthritis.
W e first investigated the im portance of IL-6, a
pleiotrophic cytokine expressed by a variety of cell types
during inflam m atory processes (24). IL-6 has com plex pro-
and antiinflam m atory influences, with both local and sys-
tem ic effects. For exam ple, it prom otes im m une responses
and plasm a cell and m acrophage differentiation (25), but
also induces acute phase proteins, IL-1 receptor antagonist
(26), and m etalloproteinase inhibitors (27). Its role is vari-
able in different inflam m atory m odels (28). There have
been conflicting reports of the requirem ent for IL-6 in an-
im al m odels of arthritis: som e investigators describe re-
duced disease in IL-6–deficient m ice or after antibody
blockade of its receptor (29, 30), whereas others report no
such effect (31).
IL-6–deficient m ice on the C57Bl/6 background (14)
were transferred with serum  from  arthritic K/BxN  m ice,
and arthritis developm ent was m onitored as described pre-
viously (6). The representative experim ent in Fig. 2 A dem -
onstrated a very sim ilar arthritis course in IL-6–deficient
and control m ice. The initial onset of sym ptom s was the
sam e, all distal joints were affected, and with a com parable
degree of inflam m ation (m easured as ankle thickness).
These observations were confirm ed by results from  three
individual experim ents tabulated in Fig. 2 B. H istological
exam ination of the ankle joints revealed the im age of syno-
vitis and joint infiltration typical of K/BxN  m ice (synovial
thickening and infiltration, presence of neutrophils in the
articular cavity, pannus form ation, and cartilage destruction;
Fig. 2 C; unpublished data). Furtherm ore, cartilage dam age
and proteoglycan loss was evident on toluidine blue–stained
ankle sections from  serum -injected m ice at com parable lev-
els for IL-6–deficient and control m ice (unpublished data).
These data are in agreem ent with those of van den Berg
and colleagues, who found little role for IL-6 in joint in-
flam m ation in CIA or zym osan-induced arthritis (31).
They contrast with other reports showing an effect of IL-6
blockade in the CIA m odel (29, 30). The explanation for
these discrepancies m ay lie in the positive im pact of IL-6
on the im m unological initiation phase of the CIA m odel:
less intense im m une responses were m ade to the colla-
gen-II antigen in the absence of IL-6 function (29, 30).
Together, then, the data are consistent with the notion that
IL-6 does not play a m ajor role in the inflam m atory effec-
tor phase of arthritis.
 
An Essential Role for IL-1.
 
Although attem pts at block-
ing the IL-1 pathway in R A patients in therapeutic trials
have not m et with as m uch success as those interfering with
the activity of TN F
  
, there exists a substantial body of evi-
dence im plicating this inflam m atory cytokine in several
Figure 1. Kinetic of inflam m a-
tory cytokine expression. Arthri-
tis was induced by injection of
K/BxN  serum  into naive
C57Bl/6 m ice, and R N A was
prepared from  ankle joint cavities
at various points thereafter.
m R N A encoding inflam m atory
cytokines were quantitated by
real-tim e PCR  using cyclophilin
m R N A as an internal standard.
The results are presented as rela-
tive expression of the individual
cytokine m R N As standardized
against a reference sam ple of total
spleen R N A from  a norm al
m ouse. This is a representative
experim ent (of three), with two
m ice pooled for each point.
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Inflam m atory Cytokines in K/BxN  Arthritis
classic m urine arthritis m odels, whether autoim m une in na-
ture or induced by local m icrobial particles (32–36); sim i-
larly, high levels of IL-1 transcripts have been detected in
R A synovium  (4, 37).
W e tested the susceptibility to serum -transferred arthritis
of the IL-1R  knockout strain (15), in which neither IL-1
  
nor IL-1
  
-m ediated signals are possible. After K/BxN  se-
rum  transfer, essentially no clinical signs of disease were ob-
served in the IL-1R –deficient m ice, except for a lim ited
swelling of the digits and a slight flutter in the ankle-thick-
ness curve (Fig. 3). To guard against possible influences of
genetic background variability, we repeated the initial
experim ents perform ed in (B6 
 
 129)F2 m ice in IL-IR –
deficient m ice thoroughly backcrossed onto the B6
background (our standard fully susceptible background;
reference 11). M atched wild-type controls responded as
usual. H istologically, no signs of joint inflam m ation were
apparent in the four m ice analyzed. N aturally, cartilage de-
struction and bone erosion were absent.
These clear-cut results indicate that, in this serum -trans-
fer m odel m ediated by arthritogenic Igs, IL-1 plays a cen-
tral role, critically required for disease progression. W e
have not been able to reproduce this effect by treatm ent
with blocking anti–IL-1R  m Ab (unpublished data), likely
because of the known difficulty to achieve com plete block-
ade of IL-1 action with biom olecule inhibitors (for review
see reference 4) The central im portance of IL-1 in the K/
BxN  m odel is rem iniscent of its requirem ent in CIA and
other m urine arthritis m odels (32, 33, 35). It is also consis-
tent with the finding that intraarticular expression of IL-1
 
,
alone, is sufficient to induce full-blown arthritis (38).
TNF Family Influences. M em bers of the TN F fam ily
have received a great deal of attention in the context of
inflam m atory arthritis. This has ranged from  the initial
dem onstration of TN F-  expression in arthritic syn-
ovium , to establishing the efficacy of TN F- -/TN FR -
blocking agents in anim al m odels, to the successes of such
reagents in therapeutic intervention in hum an R A (1, 4,
39–42). Aberrant expression of TN F-  is also sufficient to
induce arthritis in transgenic anim als (43). These results
evoked m odels of arthritogenesis in which TN F-  plays a
central and indispensable role (for review see 1). W e
tested the efficacy of K/BxN  serum  transfer in anim als
carrying knockout m utations of the genes encoding
TN F-  or its close hom ologue, lym photoxin (LT)-
(17–21). TN F-  and LT-  m ediate their pleiotropic ef-
fects by binding to one of two known receptors, TN FR 1
(p55) and TN FR 2 (p75). 
W e also investigated the effect of knockout m utations of
the genes encoding either or both of these m olecules. The
data, sum m arized in Table I, allow several conclusions.
First, and m ost sim ply, LT-  seem ed not to be required for
the developm ent of K/BxN  serum -transferred arthritis.
LT- –deficient m ice responded norm ally on all counts, in
the kinetics and intensity of inflam m ation and in the ap-
pearance of histological lesions (proliferative synovitis, infil-
tration of the joint cavity by neutrophils, and form ative of a
destructive pannus). 
Second, the absence of TN F-  had a m arked im pact on
arthritogenesis. M any TN F- –deficient m ice developed no
disease whatsoever upon transfer of K/BxN  serum , either
clinically or histologically (Table I). H owever, a num ber of
such anim als did develop joint inflam m ation, overall in 9/
Figure 2. N o requirem ent for IL-6 in arthritis induced by K/BxN  se-
rum  transfer. IL6-deficient and control m ice (m atched for gender/age and
genetic background) were injected with 150 l serum  from  arthritic
K/BxN  anim als on days 0 and 2. Arthritis was evaluated by m easuring
clinical index and ankle thickening (M aterials and M ethods). (A) Data
from  a representative experim ent, with each curve representing an indi-
vidual m ouse. (B) Tabulation of the results for 10 knockout m ice and
age/gender m atched controls; M axAT, m axim um  increase in ankle thick-
ness in m illim eters. M axCI, m axim um  clinical index, sum  of scores on
each lim b (for each lim b: 0, no disease; 0.5, m ild swelling of paw or of
just a few digits; 1, clear joint inflam m ation in ankle or wrists); m axim um
score  4. The histological score sum s scores from  knee, ankle, and tarsal
joints (1, m inim um  synovial hyperplasia; 2, lim ited inflam m atory infiltra-
tion; 3, m assive infiltration; 4, m assive infiltration with cartilage and bone
destruction); m axim um  score  12.
Figure 3. Essential role of IL-1 ILIR –deficient and control m ice
(m atched for gender/age and genetic background) were injected with 150
l serum  from  arthritic K/BxN  anim als on days 0 and 2. Arthritis was
evaluated by m easuring clinical index and ankle thickening as in Fig. 2.
(A) Data from  a representative experim ent in B6 recipients, with each
curve representing an individual m ouse. (B) Tabulation of the results for
eight knockout m ice and age/gender m atched controls on either the stan-
dard (B6  129)F2 background or on an inbred B6 background. Scoring
as described for Fig. 2; the star denotes a transient inflam m ation in the
digits of one m ouse.
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23 exam ined over the course of this study. This finding is
illustrated for representative cohorts in Fig. 4. The presence
of responder TN F /  m ice was not restricted to one or
two experim ental groups, but was observed in a num ber of
independent experim ents. In contrast, a certain degree of
clustering was observed, som e experim ental groups show-
ing a high incidence of arthritis developm ent (see below).
W hen disease did develop, the tim e of onset was quite
variable, usually delayed by several days relative to wild-
type controls, and the degree of inflam m ation always re-
m ained below the m axim um  attainable. H istological analy-
sis also revealed significant signs of inflam m ation in those
m ice with clinically detectable arthritis.
Third, joint inflam m ation developed norm ally in both
the TN FR 1- and TN FR 2-deficient m ice, as well as in
TN FR 1/TN FR 2 double–deficient anim als (Table I; the
genotypes of the m ice were reconfirm ed at the end of the
experim ent). Clinical and histological param eters were es-
sentially indistinguishable from  norm al controls. This ob-
servation was quite unexpected, as TN FR 1 and TN FR 2
are the only known receptors for TN F- , with no reported
indication of another possible receptor in spite of the broad
attention that TN F-  has received (44). As both the cyto-
kine and cytokine receptor m utations were on a susceptible
(B6  129) F2 background, one would have expected that
they have the sam e phenotype in both deficient strains.
These conflicting results prom pted us to question the ef-
fect of the TN F-  m utation: was the poor responsiveness
in TN F- –deficient m ice truly due to the absence of the
cytokine, or instead to som e independent factor (a linked
gene effect, quite plausible given the genom ic localization
of the TN F  locus; an independent m utation; protective
genes segregating by chance, etc.)? If the form er were true,
it should be possible to com plem ent the deficiency by
TN F-  replacem ent, e.g., by triggering TN FR 1 with an
agonistic m Ab. To test this prediction, we injected cohorts
of TN F -deficient m ice with K/BxN  serum , selected
those m ice that rem ained free of arthritis after 7 d, and ad-
m inistered the agonistic anti-TN FR 1 Ab 55R -593 (45). As
shown in Fig. 5, the Ab had a m arked effect, provoking ar-
thritis in all the TN F- –deficient m ice that had previously
received K/BxN  serum . N o arthritis was observed when
55R -593 was injected without serum  pretreatm ent (un-
published data). Several control m Abs were used in parallel
to rule out trivial explanations for this observation: an iso-
type-m atched control Ab, anti-TN FR 1 m Abs with block-
ing or antagonist activity (55R -170, 55R -286). N one of
these reagents induced arthritis (Fig. 5 B), at least not be-
yond the m inority of TN F- –deficient m ice one m ight
expect to eventually progress spontaneously to arthritis on
the basis of the results presented in Fig. 4. Thus, results
from  these experim ents confirm ed that TN F-  is indeed
the elem ent m issing in TN F- –deficient m ice that is re-
quired for robust developm ent of arthritis.
Table I. Arthritis Incidence in M ice Deficient in TNF and TNFR Families
Strain Arthritis Days of onset M ax CI
TN FR 1 / 8/8 4, 2, 2, 1, 1, 2, 2 3, 4, 4, 4, 4, 4, 4, 3
(B6) / 8/8 4, 2, 2, 3, 2, 3, 5, 2 4, 3, 4, 3, 4, 3.5, 2.5, 2.5
TN FR 2 / 8/8 4, 2, 2, 1, 1, 1, 2, 2 3, 4, 4, 4, 4, 4, 4, 3
(B6) / 8/8 1, 4, 1, 1, 1, 1, 1, 2 4, 4, 4, 4, 4, 4, 4, 3.5
TN FR 1/2 / 6/6 2, 2, 1, 4, 2, 2 4, 4, 4, 1.5, 3.5, 3
(B6x129F2) / 6/6 3, 7, 2, 2, 2, 2 2.5, 0.5,4, 4, 4, 4
Lt / 8/8 2, 2, 2, 2, 2, 1, 4, 2 4, 4, 4, 4, 4, 2, 4, 3
(B6x129F2) / 8/8 2, 2, 5, 3, 2, 2, 2, 2 2, 2, 3, 3, 4, 4, 4, 4
TN F / 9/9 2, 2, 2, 3, 5, 4, 2, 3, 3 2.5, 4, 4, 4, 2, 4, 4, 2.5, 3.5
(B6x129F2) / 4/14 -, -, -, -, 8, 19, -, -, - 0, 0, 0, 0, 1.5, 1, 0, 0, 0
2, 5, -, -, -, 1 4, 1.5, 0.5, 0.5, 0.5
Figure 4. Variability of arthritis in TN F -deficient m ice. TN F -defi-
cient (left) and control m ice (right; m atched for gender/age and genetic
background) were injected with 150 l serum  from  arthritic K/BxN  ani-
m als on days 0 and 2. Arthritis was evaluated by m easuring ankle thicken-
ing as in Fig. 2. The data are pooled from  six different experim ents. All
m ice originated from  the Jackson Laboratory.
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Further experim ents were perform ed to address the
cause of the variable effect of the TN F-  deficiency. It
could be explained by genetic, epigenetic, or environm en-
tal variation controlling the activity of TN F- –indepen-
dent pathways; stochastic threshold effects could also be in-
volved, arthritogenesis requiring a certain degree of local
inflam m atory insult, only seldom  reached in the absence of
TN F- . As the knockout m utation was carried on a m ixed
(129xB6) F2 background, we reasoned that m odifier alleles
at other loci, able to com plem ent the TN F deficiency,
m ight segregate random ly in the F2 knockout m ice. To
test this hypothesis, several crosses were set up between
com binations of resistant or susceptible TN F- –deficient
m ice. Should alleles at independent loci be segregating,
there should be heritable transm ission of these traits to the
progeny. As shown in Fig. 6 A, this was not the case. A
cross between two resistant m ice yielded a dom inant pro-
portion of responder m ice; the transm ission of a recessive
susceptibility allele in this fam ily would be very unlikely to
yield such a pattern (P  0.001). Thus, the variability does
not stem  from  M endelian genetic elem ents. Epigenetic
variation could perhaps account for these results. H owever,
we observed a clear correlation between the origin and life
history of the m ice and their responses to K/BxN  serum
(Fig. 6 B). Those m ice bred at the Jackson Laboratory and
shipped to Boston 7–15 d before challenge showed m ainly
a resistant phenotype, whereas those bred in Boston and
tested there were m ainly susceptible (P  0.003). In both
cases, the barrier facilities have SPF status, free of m ajor
m ouse pathogens, but m inor bacterial flora varies. Thus,
the segregation of responses is m ore consistent with an en-
vironm ental explanation than with an epigenetic one.
Together, these experim ents point to a distinct involve-
m ent of TN F-  in Ab-induced arthritis, but one that is not
absolutely essential. This conclusion differs from  that
reached by Kyburz et al. (13), who found no effect of anti-
TN F-  therapy in arthritis developm ent in straight K/BxN
transgenic m ice. W e have also m ade sim ilar observations,
injecting several different anti-TN F-  reagents into young
K/BxN  m ice (unpublished data). H owever, we interpret
these negative results with caution because of the very ag-
gressive nature of the disease that develops in the transgenic
mice and uncertainties concerning the efficiency of Ab-medi-
ated blockade. O n the other hand, the present results do
concur with reports of robust developm ent of CIA in TN F-
–deficient m ice (46). Although it is conceivable that the
cytokine network adapts som ewhat in TN F- –deficient an-
im als, other com pensatory cytokines being m ore active than
usual, the results do show that TN F-  is not the indispens-
able cytokine for the developm ent of Ab-induced arthritis.
The significant m ouse-to-m ouse variability we observed
with TN F- –deficient anim als is, in a sense, rem iniscent of
the variability in the response of R A patients to TN F- /
TN FR  blockade (1). The results of Fig. 6 m ake it perhaps
m ore plausible that environm ental effects are at play, the
degree of TN F-  involvem ent being dependent on the
general inflam m atory state of the individual. It should be
worthwhile trying to pinpoint what these influences m ight
be, in both m ice and hum ans, and the present system  does
provide a handle.
There are several potential interpretations for the strong
arthritis that develops in TN FR 1/2-deficient m ice. The
m ost straightforward is that other receptors can com pensate
and m ediate TN F-  signals. Although the existence of such
a receptor has not been reported to date, the breadth of the
TN FR  fam ily m akes it quite possible that other receptors
will be found to bind TN F- . W hether these are indeed
the prim ary receptors m ediating arthritis, or whether they
only com e into play when the prim ary TN FR 1/2 receptors
are absent, will need to be explored. Alternatively, one
m ight propose that TN F- –independent arthritis pathways
are particularly active when TN FR 1/2 are m issing, perhaps
by com m andeering downstream  signal transduction adap-
Figure 5. Triggering the TN F receptor com plem ents TN F  defi-
ciency. TN F -deficient m ice were injected with 150 l serum  from  ar-
thritic K/BxN  anim als on days 0 and 2. Anim als not presenting any signs
of disease by day 7 were injected at days 7, 11, and 15 with anti-TN FR 1
m Ab 55R -293, which has significant agonist activity (A) or with control
m Abs (B). These controls included anti-TN FR 1 reagents devoid of ago-
nist activity or an irrelevant m Ab. (C) Anti-TN FR  m Abs were injected
without K/BxN  serum . Arthritis was evaluated by m easuring ankle thick-
ening as above. The data are pooled from  four different experim ents. All
m ice originated from  the Jackson Laboratory.
Figure 6. Environm ental, not genetic, influences on TN F-indepen-
dent arthritis. (A) TN F -deficient m ice from  the Jackson Laboratory
were tested by transfer of K/BxN  serum , and anim als of different pheno-
types were crossed (white sym bols, resistant m ice; black sym bols, suscep-
tible m ice, where resistance and susceptibility are defined as the presence
of clear arthritis [grade  1]) in the first 10 d after serum  transfer. Their
progeny was sim ilarly tested when 4–5 wk old. (B) A com pilation of re-
sults of challenge of TN F -deficient m ice with K/BxN  serum , either
from  m ice purchased from  the Jackson Laboratory or bred in our Boston
colony; 2, P  0.003.
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tors. For exam ple, the absence of TN FR 1 m ight free
TR ADD, FADD, or TR AF m olecules for m ore efficient
interaction with other receptors.
Bone Destruction and Formation. There is som e debate
about the role of inflam m atory cytokines in prom oting fo-
cal bone erosion in the course of arthritic diseases. O steo-
clasts are essential to the process, and essentially no focal
destruction of the bone occurs in their absence. R esistance
to bone erosion was previously dem onstrated in m ice defi-
cient in the TN F fam ily m em ber receptor activator of N F-
KB ligand (R AN KL) that had received K/BxN  serum , as
in the CIA m odel after blockade of R AN KL by osteopro-
tegerin treatm ent (23, 47). This finding is consistent with
the fact that R AN K/R AN KL axis is required for the gen-
eration of osteoclasts and also plays a role in their activation
(for review see reference 48). In contrast, it is also possible
that other inflam m atory cytokines play a role. IL-1  can
activate osteoclasts, and prom otes bone resorption in vitro
(49, 50). TN F prom otes osteoclast differentiation in the
presence of R AN KL (51, 52), and there are indications that
TN F/TN FR  blockade can retard bone destruction in R A
patients, even when the effect on the inflam m atory com -
ponent is lim ited (53). Thus, we asked whether bone de-
struction could be seen in the absence of these cytokines.
As described previously, obvious instances of focal bone
destruction were seen in norm al m ice injected with K/
BxN  serum ; sim ilar im ages were also observed in LT -
deficient m ice (Fig. 7, A and B). For TN F- , we focused
in particular on those m ice that showed significant joint in-
flam m ation. In these instances, clear evidence of focal bone
destruction was also observed (Fig. 7 C). Although im pos-
sible to truly quantitate, given the variability of inflam m a-
tion in the TN F-deficient anim als, the extent of the erosive
lesions in the absence of TN F-  was largely on par with
the extent of inflam m ation.
W e could not draw any conclusion on the role of IL-1 in
bone destruction, as the upstream  inflam m atory phase did
not develop in its absence. H owever, our results are not
consistent with the view that TN F-  plays an obligate role
in prom oting bone destruction: synovitis and joint inflam -
m ation could still lead to extensive destruction in its absence.
Synthesis: Intersection of IL-1 and TNF Pathways. There
has been quite som e debate as to the relative roles and im -
portance of IL-1 and TN F-  in arthritogenesis. In anim al
m odels where the function of these cytokines has been
tested, their im portance varies som ewhat with the disease-
eliciting agent, although IL-1 m ay play a dom inant role in
the cartilage and bone destruction that ultim ately ensues
(for review see reference 4). For Ab-m ediated arthritis that
the K/BxN  disease m ay typify, our results point to a m ore
crucial function for IL-1. These roles, and the slightly dif-
ferent kinetics of induction of cytokine transcription in the
joint during arthritis initiation, are consistent with a m odel
in which the point of action of TN F-  would be upstream
of that of IL-1 (1). TN F- –independent pathways, perhaps
relying on other m em bers of the TN F fam ily, m ay also
trigger IL-1 independently. This view is consistent with
the im portance of TN F-  in prom oting IL-1 production
by synoviocytes from  R A patients (54), or with the fact
that IL-1 blockade prevents the arthritis induced by trans-
gene-encoded TN F-  m isexpression (34). It should also be
pointed out that the experim ents shown in Fig. 1 only de-
tect transcriptionally induced TN F-  production. H ow-
ever, it is likely that even earlier release of TN F-  occurs
in the first m inutes or hours of the disease, released from
intracellular stores of synoviocytes or m ast cells upon trig-
gering by C5a or Fc R III. These m olecules constitute two
essential links between the anti-GPI Abs and the inflam -
m atory m anifestations of K/BxN  arthritis (11), and both
pathways are known to precipitate rapid TN F-  release.
The relevance of the Ab-m ediated arthritis m odel that
K/BxN  m ice present to hum an arthritic diseases had been
questioned, in part, because it does not fit well with the
paradigm  in which autoreactive T cells within the joint
provoke local TN F-  release, a m odel bolstered by the
Figure 7. Bone destruction in control and KO  m ice. Bone erosion was
assessed in hem atoxylin and eosin–stained ankle sections from  TN F -
and LT -deficient m ice and control m ice after transfer of K/BxN  serum .
(A) Control m ouse, full inflam m ation and areas of focal bone destruction
(arrows). (B) Arthritic LT -deficient m ouse with inflam m ation and focal
bone erosion. (C) TN F -deficient m ouse with clinical m anifestations,
showing inflam m ation and focal bone erosion. (D) TN F -deficient
m ouse with no clinically detectable sym ptom s, showing m inim al in-
flam m ation (m atched with A).
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successes of anti–TN F-  therapy. The present results show
that arthritis induced by Ab com plexes in the joint also end
up with the production of TN F-  and IL-1, and is highly
dependent on these cytokines.
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